The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The therapeutic potential of CRF1 antagonists for anxiety
Abstract
Preclinical studies suggest that the brain corticotropin-releasing factor (CRF) systems mediate anxiety-like behavioural and somatic responses through actions at the CRF1 receptor. CRF1 antagonists block the anxiogenic-like effects of CRF and stress in animal models. Cerebrospinal fluid levels of CRF are elevated in some anxiety disorders and normalise with effective treatment, further implicating CRF systems as a therapeutic target. Prototypical CRF1 antagonists are highly lipophilic, non-competitive antagonists of peptide ligands. Modification of the chemotype and the identification of novel pharmacophores are yielding more drug-like structures with increased hydrophilicity at physiological pHs. Newer compounds exhibit improved solubility, pharmacokinetic properties, potency and efficacy. Several clinical candidates have entered Phase I/II trials. However, unmet challenges await resolution during further discovery, clinical development and therapeutic application of CRF1 antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Swanson, L. W., Sawchenko, P. E., Rivier, J., & Vale, W. W. (2008) · Neuroendocrinology · doi:10.1159/000123454 · Cited by 1,953
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Dunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352
The economic burden of anxiety disorders in the 1990s
Greenberg, P. E., Sisitsky, T., Kessler, R. C., Finkelstein, S. N., Berndt, E. R., Davidson, J. R. T., Ballenger, J. C., & Fyer, A. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0702 · Cited by 1,242 · cited 1×
“Anxiety disorders impair quality of life as much as other common, chronic medical conditions [3,11] and account for one-third of the financial burden of all mental illness in the US [2,13,14].”
BackgroundThe quality of care for depressive and anxiety disorders in the United States
Young, A. S., Klap, R., Sherbourne, C. D., & Wells, K. B. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.1.55 · Cited by 1,061
DSM-III-R Generalized Anxiety Disorder in the National Comorbidity Survey
Wittchen, H.-U. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950050015002 · Cited by 967
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955
Lewis, K., Li, C., Perrin, M. H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T. M., Gulyas, J., Fischer, W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121165198 · Cited by 925
Timpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J. M. H. M., Stalla, G. K., Blanquet, V., Steckler, T., Holsboer, F., & Wurst, W. (1998) · Nature Genetics · doi:10.1038/520 · Cited by 919
Smith, G. W., Aubry, J.-M., Dellu, F., Contarino, A., Bilezikjian, L. M., Gold, L. H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C. A., et al. (1998) · Neuron · doi:10.1016/s0896-6273(00)80491-2 · Cited by 892
Self-citationReyes, T. M., Lewis, K., Perrin, M. H., Kunitake, K. S., Vaughan, J., Arias, C. A., Hogenesch, J. B., Gulyas, J., Rivier, J., Vale, W. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051626398 · Cited by 887
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.5.624 · Cited by 721
Benzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560
Kendler, K. S., Davis, C. G., & Kessler, R. C. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.6.541 · Cited by 412 · cited 2×
“rank-ordered oral bioavailabilities of antalarmin (19% [295]) < CP-154526 (27% [296]) < DMP-904 (33% [283]) < DMP-696 (37 – 50% [294]) mimic the inverse rank of their cLogD values (Pearson r [4] = -0.”
BackgroundRassnick, S., Heinrichs, S. C., Britton, K. T., & Koob, G. F. (1993) · Brain Research · doi:10.1016/0006-8993(93)91352-s · Cited by 407
Self-citationRadulovic, J., Rühmann, A., Liepold, T., & Spiess, J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05016.1999 · Cited by 402
Butler, P., Weiss, J., Stout, J., & Nemeroff, C. (1990) · The Journal of Neuroscience · doi:10.1523/jneurosci.10-01-00176.1990 · Cited by 402
Corticotropin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide
Swerdlow, N. R., Geyer, M. A., Vale, W. W., & Koob, G. F. (1986) · Psychopharmacology · doi:10.1007/bf00652231 · Cited by 299
Self-citationGrillon, C., Morgan, C. A., Davis, M., & Southwick, S. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00034-1 · Cited by 263
Deak, T., Nguyen, K. T., Ehrlich, A. L., Watkins, L. R., Spencer, R. L., Maier, S. F., Licinio, J., Wong, M.-L., Chrousos, G. P., Webster, E., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6415 · Cited by 242
Judd, L. L., Kessler, R. C., PauIus, M. P., Zeller, P. V., Wittchen, H. ‐., & Kunovac, J. L. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05960.x · Cited by 222 · cited 1×
“Anxiety disorders co-occur with other psychiatric [1,4-7] and non-psychiatric [8-10] medical conditions, complicating their course and severity [11,12].”
BackgroundGrillon, C., Morgan, C. A., Southwick, S. M., Davis, M., & Charney, D. S. (1996) · Psychiatry Research · doi:10.1016/s0165-1781(96)02942-3 · Cited by 221
Liebsch, G., Landgraf, R., Gerstberger, R., Probst, J. C., Wotjak, C. T., Engelmann, M., Holsboer, F., & Montkowski, A. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00099-w · Cited by 220
Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex
Liang, K., Melia, K., Miserendino, M., Falls, W., Campeau, S., & Davis, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-06-02303.1992 · Cited by 203
Valdez, G. R., Zorrilla, E. P., Roberts, A. J., & Koob, G. F. (2003) · Alcohol · doi:10.1016/s0741-8329(03)00020-x · Cited by 186
Self-citationPrevalence of irritable bowel syndrome among university students
Hazlett-Stevens, H., Craske, M. G., Mayer, E. A., Chang, L., & Naliboff, B. D. (2003) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(03)00019-9 · Cited by 170
Sautter, F. J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B., Myers, L., Johnson, J. E., Cerbone, A., & Malaspina, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00571-7 · Cited by 162
Prepulse inhibition deficits in patients with panic disorder
Ludewig, S., Ludewig, K., Geyer, M. A., Hell, D., & Vollenweider, F. X. (2002) · Depression and Anxiety · doi:10.1002/da.10026 · Cited by 157
Role of the Amygdala in Fear Extinction Measured with Potentiated Startle
DAVIS, M., WALKER, D. L., & MYERS, K. M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07084.x · Cited by 152
Comorbidity of irritable bowel syndrome in psychiatric patients: A review
Garakani, A., Win, T., Virk, S., Gupta, S., Kaplan, D., & Masand, P. S. (2003) · American Journal of Therapeutics · doi:10.1097/00045391-200301000-00014 · Cited by 149
Heinrichs, S. C., Menzaghi, F., Pich, E. M., Baldwin, H. A., Rassnick, S., Britton, K. T., & Koob, G. F. (1994) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380104 · Cited by 143
Self-citationStinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300487 · Cited by 139
Self-citationCorticotropin-releasing factor administered intraventricularly to rhesus monkeys
Kalin, N. H., Shelton, S. E., Kraemer, G. W., & McKinney, W. T. (1983) · Peptides · doi:10.1016/0196-9781(83)90117-1 · Cited by 101
Nijsen, M. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00167-6 · Cited by 92
Schall, U., Schön, A., Zerbin, D., Eggers, C., & Oades, R. D. (1996) · International Journal of Neuroscience · doi:10.3109/00207459608987247 · Cited by 71
VIETA, E., MARTÍNEZ-DE-OSABA, M. J., COLOM, F., MARTÍNEZ-ARÁN, A., BENABARRE, A., & GASTÓ, C. (1999) · Psychological Medicine · doi:10.1017/s0033291799008727 · Cited by 62
Kalin, N. H., & Takahashi, L. K. (1990) · Brain Research · doi:10.1016/0006-8993(90)90311-x · Cited by 59
de Jongh, R., Groenink, L., van der Gugten, J., & Olivier, B. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00468-2 · Cited by 54
Suppression of Conditioned Fear by Administration of CRF Receptor Antagonist CP-154,526
Hikichi, T., Akiyoshi, J., Yamamoto, Y., Tsutsumi, T., & Isogawa, K. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-7587 · Cited by 47
Cited by
Addiction and the brain antireward system
Koob, G. F., & Le Moal, M. (2008) · Annual Review of Psychology · doi:10.1146/annurev.psych.59.103006.093548 · Cited by 1,457
Self-citationStress dysregulation of drug reward pathways, and the transition to drug dependence
Koob, & Kreek, M. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05030503 · Cited by 868
Role of Corticotropin-Releasing Factor in Drug Addiction: Potential for Pharmacological Intervention
Logrip, M. L., Koob, G. F., & Zorrilla, E. P. (2011) · CNS Drugs · doi:10.2165/11587790-000000000-00000 · Cited by 476
Self-citationFunk, C. K., O'Dell, L. E., Crawford, E. F., & Koob, G. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3096-06.2006 · Cited by 381
Self-citationPharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Metadata
- Authors
- Zorrilla, E. P., & Koob, G. F.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2004-07
- Volume
- 13
- Issue
- 7
- Pages
- 799-828
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2062976494
- Cited by
- 176
- References
- 41
- FWCI
- 5.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.